The FEBS Journal
Epithelial‐to‐mesenchymal‐like transition events in melanoma
The FEBS Journal, Volume 289, Issue 5, Page 1352-1368, March 2022.
The FEBS Journal
The transcriptional regulation of normal and malignant blood cell development
The FEBS Journal, Volume 289, Issue 5, Page 1240-1255, March 2022.
The FEBS Journal
Issue Information
The FEBS Journal, Volume 289, Issue 5, Page 1153-1155, March 2022.
The FEBS Journal
Clinical advances in targeting epigenetics for cancer therapy
The FEBS Journal, Volume 289, Issue 5, Page 1214-1239, March 2022.
The FEBS Journal
EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms
The FEBS Journal, Volume 289, Issue 5, Page 1329-1351, March 2022.
The FEBS Journal
The duality of PRDM proteins: epigenetic and structural perspectives
The FEBS Journal, Volume 289, Issue 5, Page 1256-1275, March 2022.
The FEBS Journal
Cancer epigenetics: promises and pitfalls for cancer therapy
The FEBS Journal, Volume 289, Issue 5, Page 1156-1159, March 2022.
The FEBS Journal
Physical mechanisms of chromatin spatial organization
The FEBS Journal, Volume 289, Issue 5, Page 1180-1190, March 2022.
The FEBS Journal
Table of Contents
The FEBS Journal, Volume 289, Issue 5, Page 1369-1369, March 2022.
The FEBS Journal
A guide to enzyme kinetics in early drug discovery
The FEBS Journal, Volume 290, Issue 9, Page 2292-2305, May 2023.